Nepresol in the treatment of hypertension of major severity.
Fifty patients with arterial hypertension of various causes were treated with a combination consisting of Nepresol, a beta-adrenergic receptor-blocking agent and a diuretic. Duration of treatment ranged between 3 months and 5 years. A significant reduction of blood pressure was attained in all of the cases, with a return of the values to the normal range in a high proportion of the patients. The renal function did not deteriorate during therapy, but owing to potassium loss regular potassium replacement was required in the majority of the cases. Allergic reactions appeared in two cases. Neither SLE nor rheumatoid arthritis was encountered. Positive ANF reaction and a significant elevation of the Rose-Waaler titre were demonstrated in a number of cases. The benefits as well as the hazards of the therapeutic use of hydrazine derivatives are pointed out.
D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D001806:Blood Urea Nitrogen; D002986:Clinical Trials as Topic; D003404:Creatinine / Q000097:blood; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006830:Hydralazine / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D006852:Hydrochlorothiazide / Q000008:administration & dosage; D006973:Hypertension / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011188:Potassium / Q000097:blood; D011433:Propranolol / Q000008:administration & dosage; D012964:Sodium / Q000097:blood
D006852:Hydrochlorothiazide; D006830:Hydralazine; D012964:Sodium; D011433:Propranolol; D003404:Creatinine; D011188:Potassium